Zobrazeno 1 - 10
of 1 047
pro vyhledávání: ''
Autor:
Jinying Shen, Yujie Zhao, Linhai Zhong, Tianhui Hu, Xiong Chen, Xiaolin Xu, Daxuan Wang, Yan-yan Zhan, Xiaoting Hong, Hanwei Cao, Yitong Zhou, Jianben Wu, Ying Lin, Wenqing Zhang, Jihuan Hou
Publikováno v:
Cancer Research. 81:5904-5918
Invasive mucinous lung adenocarcinoma (IMA) is a subtype of lung adenocarcinoma with a strong invasive ability. IMA frequently carries "undruggable" KRAS mutations, highlighting the need for new molecular targets and therapies. Nuclear receptor HNF4
Autor:
Cory Abate-Shen, Amir Lankarani, Matteo Di Bernardo, Michael M. Shen, Rivka L. Shoulson, Soonbum Park, Lijie Rong, Tomasz Owczarek, Talal Syed, Hikmat Al-Ahmadie, David B. Solit, James M. McKiernan, Chee-Wai Chua, Prithi Chakrapani, Jaime Y. Kim
Publikováno v:
Cancer Res
To study the progression of bladder cancer from non–muscle-invasive to muscle-invasive disease, we have developed a novel toolkit that uses complementary approaches to achieve gene recombination in specific cell populations in the bladder urotheliu
Autor:
Lei Bi, Fuqiong Zhou, Peng Meng, Bo Tang, Yidan Ren, Yunshan Wang, Yu-Cui Jiang, Weiping Chen, Qin Wang, Chuanxin Wang, Maoxiao Feng, Yuli Wang, Feiyan Chen, Qinlian Jiao, Lutao Du
Publikováno v:
Cancer Research. 81:2015-2028
Hepatocellular carcinoma (HCC) contains a subset of cancer stem cells (CSC) that cause tumor recurrence, metastasis, and chemical resistance. Histone deacetylase 11 (HDAC11) mediates diverse immune functions and metabolism, yet little is known about
Autor:
Eva Ciruelos, Ingrid A. Mayer, Chong Ma, Sibylle Loibl, Dejan Juric, Albert Reising, Hope S. Rugo, Michelle Miller, Hiroji Iwata, Mario Campone, Pierfranco Conte, Fabrice Andre, Naveen Babbar, Monica Arnedos
Publikováno v:
Cancer Research. 81:PD2-06
Introduction: The PI3K pathway is often hyperactivated in cancer as a result of an altered PI3K isoform and/or loss of phosphatase and tensin homolog function. Approximately 40% of patients (pts) with hormone receptor-positive (HR+), human epidermal
Autor:
Emad A. Rakha, David M. Heery, Cíntia J. Monteiro, Kartikeya Bhardwaj, Nigel P. Mongan, Wilbert Zwart, Mansour Alsaleem, Steffi Oesterreich, Takaaki Fujii, Ian O. Ellis, Andrew R. Green, Stacey E. P. Joosten, Sasagu Kurozumi, Ken Shirabe, Simon J Johnston
Publikováno v:
Cancer Research. 81:PS6-11
Invasive lobular carcinoma (ILC) accounts for 10-15% of primary breast cancer and is typically ER+ and ERBB2 non-amplified. There is preclinical evidence that somatic ERBB2 mutation may provide an alternative and tractable mechanism for upregulation
Autor:
Jianying Zhou, Tejaswini P. Reddy, Hongbin Wang, Stacy L. Moulder, Wei Qian, Roberto R. Rosato, Jenny C. Chang, Helen Piwnica-Worms, Liliana Guzman
Publikováno v:
Cancer Research. 81:PS11-17
Metaplastic breast cancer (MpBC) is a rare subset accounting for less than 1% of all breast cancers. MpBC exhibits the worst prognosis in comparison to triple-negative breast cancer (TNBC) with a dismal poor survival rate in patients with metastatic
Autor:
Linda A. deGraffenried, Aleksandra Gruslova, Andrew Brenner, Christopher A. Jolly, Bryan Mcclellan
Publikováno v:
Cancer Research. 81:PS17-26
INTRODUCTION: Estrogen receptor-positive (ER+) breast cancer accounts for nearly 70% of all cases. Common targeted anti-estrogen therapies such tamoxifen, fulvestrant and aromatase inhibitors have shown success in the clinic, but unfortunately, often
Autor:
Winfried R. Mulder, Lisa D. Eli, Neil T Conlon, Denis M. Collins, Suzanne J.C. van Gerwen, Alshad S. Lalani, Jeffrey J. Kooijman, Irmina Diala, John Crown, Guido J.R. Zaman
Publikováno v:
Cancer Research. 81:PS10-06
Introduction: Human epidermal growth factor 2 (HER2/ERBB2) is frequently amplified or mutated across various cancer types. The tyrosine kinase inhibitors (TKIs) lapatinib, neratinib, and tucatinib are FDA-approved for the treatment of HER2-positive b
Autor:
Nikhil C. Munshi, Daisuke Tsuchimoto, Mei Yin, Allison J. Janocha, Yi Hu, Hua Fang, Shan Yan, Thomas LaFramboise, Li Xue, Alex Mejia-Garcia, Chen Li, Chun Yang, Jennifer S. Yu, Jianhong Lin, Kenneth C. Anderson, Chuanfeng Fang, Yusaku Nakabeppu, Qing Y. Zheng, Tania Amorim, Xin Qi, Leal Herlitz, Faiz Anwer, Jenny Lin, Jack Khouri, Mohsin Maqbool, Ariel Kwart, Xiaofeng Jiang, Jianjun Zhao
Publikováno v:
Cancer Res
Cisplatin chemotherapy is standard care for many cancers but is toxic to the kidneys. How this toxicity occurs is uncertain. In this study, we identified apurinic/apyrimidinic endonuclease 2 (APE2) as a critical molecule upregulated in the proximal t
Autor:
Carsten Sticht, Carolin Mogler, Olga Ermakova, Fabian Rose, Stefan Thomann, Eduard Ryschich, Carolina De La Torre, Daniel Kazdal, Kai Breuhahn, Claudia R. Ball, Norbert Gretz, Stephanie Roessler, Simone Marquard, Sarah Fritzsche, Peter Schirmacher, S Weiler, Teng Wei, Eugen Rempel, Hanno Glimm, Marcell Tóth
Publikováno v:
Cancer Research. 80:5502-5514
The oncogene yes-associated protein (YAP) controls liver tumor initiation and progression via cell extrinsic functions by creating a tumor-supporting environment in conjunction with cell autonomous mechanisms. However, how YAP controls organization o